Medpace Holdings Inc
NASDAQ:MEDP
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
277.23
618.49
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one
MEDP
stock under the Base Case scenario is
380.41
USD.
Compared to the current market price of 560.22 USD,
Medpace Holdings Inc
is
Overvalued by 32%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.
Let our AI break down the key assumptions behind the intrinsic value calculation for Medpace Holdings Inc.
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
|
| FR |
|
Sartorius Stedim Biotech SA
PAR:DIM
|
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Medpace’s heavy reliance on smaller biotech and emerging pharma clients could backfire if funding conditions tighten, as these customers often struggle to secure sustained capital for drug development, directly impacting Medpace’s project pipeline and revenue growth.
Compared to major CRO peers that offer broader therapeutic coverage and global footprints, Medpace could see stalled contract wins or more pricing pressure, given its narrower focus and smaller scale in an increasingly consolidated industry.
Medpace’s aggressive expansion into new service offerings risks operational inefficiencies and elevated overhead if integration costs outstrip near-term project revenue, pressuring profitability and straining its balance sheet.
Medpace’s niche expertise in full-service clinical trial management for small to mid-sized biotech firms positions it to capture growing demand for specialized drug development support, particularly in oncology and rare diseases where innovation is robust.
Its high-touch, integrated service model fosters close client relationships and repeat business, allowing Medpace to differentiate effectively from larger competitors that often struggle to provide the same level of customization and attention.
Strong operating margins and disciplined cost control underscore Medpace’s ability to generate solid free cash flow, which supports reinvestment in new service capabilities and potential strategic acquisitions that further broaden its offerings.
Revenue & Expenses Breakdown
Medpace Holdings Inc
Balance Sheet Decomposition
Medpace Holdings Inc
| Current Assets | 737.3m |
| Cash & Short-Term Investments | 285.4m |
| Receivables | 373m |
| Other Current Assets | 78.9m |
| Non-Current Assets | 1B |
| PP&E | 256.8m |
| Intangibles | 696.1m |
| Other Non-Current Assets | 62.9m |
| Current Liabilities | 1.3B |
| Accounts Payable | 26.5m |
| Accrued Liabilities | 393.7m |
| Other Current Liabilities | 863.7m |
| Non-Current Liabilities | 175.5m |
| Other Non-Current Liabilities | 175.5m |
Free Cash Flow Analysis
Medpace Holdings Inc
| USD | |
| Free Cash Flow | USD |
Earnings Waterfall
Medpace Holdings Inc
|
Revenue
|
2.4B
USD
|
|
Cost of Revenue
|
-1.6B
USD
|
|
Gross Profit
|
733.6m
USD
|
|
Operating Expenses
|
-226.6m
USD
|
|
Operating Income
|
507m
USD
|
|
Other Expenses
|
-74m
USD
|
|
Net Income
|
433m
USD
|
MEDP Profitability Score
Profitability Due Diligence
Medpace Holdings Inc's profitability score is 72/100. The higher the profitability score, the more profitable the company is.
Score
Medpace Holdings Inc's profitability score is 72/100. The higher the profitability score, the more profitable the company is.
MEDP Solvency Score
Solvency Due Diligence
Medpace Holdings Inc's solvency score is 76/100. The higher the solvency score, the more solvent the company is.
Score
Medpace Holdings Inc's solvency score is 76/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MEDP Price Targets Summary
Medpace Holdings Inc
According to Wall Street analysts, the average 1-year price target for
MEDP
is 547.08 USD
with a low forecast of 305.23 USD and a high forecast of 687.75 USD.
Dividends
Current shareholder yield for
MEDP is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
MEDP
stock under the Base Case scenario is
380.41
USD.
Compared to the current market price of 560.22 USD,
Medpace Holdings Inc
is
Overvalued by 32%.